They are associated with increased apoptosis in hepatocytes and leukocytes, suggesting IL-6R as a potential biomarker of MASLD progression (109) and in patients with obesity and MASH, increased soluble glycoprotein 130 (sgp130), which belongs to the IL-6 family, correlate with glycated hemoglobin (HbA1c), liver stiffness, and advanced fibrosis, indicating that glucose metabolic dysregulation may intensify IL-6 activity and worsen MASLD (110). Here, IL6 is linked to metabolic dysfunction-associated steatotic liver disease.